Stories

On Rare Disease Day 2026, we explore AlveoGene – the company developing inhaled gene therapies for rare diseases that are currently fatal. It’s a research story 25 years in the making.

On International Day of Women and Girls in Science, we asked women in our HealthTech, Life Sciences and Deep Tech teams how we can move from awareness to action.

From academic breakthrough to $1bn acquisition – a story of deep science, patient capital, and bold ambition.

Ultromics is transforming how we detect heart disease. Its AI tool EchoGo® reveals hard-to-spot signs of heart failure, helping close one of medicine’s deadliest diagnostic gaps.

From school drop-out to professor at Oxford and biotech founder, Dame Carol Robinson’s journey has changed the future of drug discovery.

Katherine Ward has spent her career working at the intersection of innovation and adoption in the HealthTech space. 

Alethio Therapeutics is redefining how we treat incurable blood cancers – by targeting the cells that drive them.

How a unique team of experts founded a clean energy pioneer – thanks to strategic partnerships and venture building support from Oxford Science Enterprises.

How Nucleome Therapeutics is decoding the ‘non-coding genome’ to accelerate drug discovery breakthroughs.

Kneu Health uses AI and a smartphone app to support better diagnosis, treatment, and care for people with dementia and Parkinson’s.

Founded by visionary scientist Walter Goodwin, Fractile is designing powerful, efficient silicon to radically scale the next generation of AI.

The OSE spinout that’s pioneering gene therapies to slow or stop blindness caused by retinal diseases.